Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
Citations Over TimeTop 10% of 2018 papers
Abstract
Drug transporters can govern the absorption, distribution, metabolism, and excretion of substrate drugs and endogenous substances. Investigations to examine their potential impact to pharmacokinetic (PK) drug-drug interactions (DDIs) are an integral part of the risk assessment in drug development. To evaluate a new molecular entity as a potential perpetrator of transporters, use of well characterized and/or clinically relevant probe substrates with good selectivity and sensitivity are critical for robust clinical DDI assessment that could inform DDI management strategy in the product labeling. The availability of endogenous biomarkers to monitor transporter-mediated DDIs in early phases of clinical investigations would greatly benefit downstream clinical plans. This article reviews the state-of-the-art in transporter clinical probe drugs and emerging biomarkers, including current challenges and limitations, delineates methods and workflows to identify and validate novel endogenous biomarkers to support clinical DDI evaluations, and proposes how these probe drugs or biomarkers could be used in drug development.
Related Papers
- → The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection(2019)3 cited
- → Pharmacokinetics of 2',3'-dideoxyinosine in monkeys(1991)20 cited
- Pharmacokinetics of monoclonal antibody HAb 18 and its F(ab^)_(2) and fab fragments in mice(1996)
- Pharmacokinetics and tissue distribution of Chuanhuning emuslion in rats(2014)